Silk Road Medical (SILK) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2233493/silk-road-medical-silk-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233493
Feb 28, 2024 - Silk Road Medical (SILK) delivered earnings and revenue surprises of 17.50% and 11.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Why Nvidia (NVDA) is a Top Stock for the Long-Term
https://www.zacks.com/stock/news/2233176/why-nvidia-nvda-is-a-top-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_focus_list-2233176
Feb 28, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
0
Establishment Labs Holdings Inc. (ESTA) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2233411/establishment-labs-holdings-inc-esta-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233411
Feb 28, 2024 - Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 16.84% and 0.06%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
AMC Entertainment (AMC) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2233503/amc-entertainment-amc-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233503
Feb 28, 2024 - AMC Entertainment (AMC) delivered earnings and revenue surprises of 22.86% and 3.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Why Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2233209/why-doctor-reddy-s-rdy-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2233209
Feb 28, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
MBIA (MBI) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2233517/mbia-mbi-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233517
Feb 28, 2024 - MBIA (MBI) delivered earnings and revenue surprises of -500% and 12.50%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Butterfly Network, Inc. (BFLY) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2233436/butterfly-network-inc-bfly-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233436
Feb 28, 2024 - Butterfly Network, Inc. (BFLY) delivered earnings and revenue surprises of -75% and 3.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
https://www.zacks.com/stock/news/2233504/codexis-cdxs-tops-q4-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233504
Feb 28, 2024 - Codexis (CDXS) delivered earnings and revenue surprises of 112.50% and 7.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
Why FirstEnergy (FE) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2233261/why-firstenergy-fe-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2233261
Feb 28, 2024 - Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
0
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
https://www.zacks.com/stock/news/2233520/catalyst-pharmaceutical-cprx-tops-q4-earnings-and-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2233520
Feb 28, 2024 - Catalyst (CPRX) delivered earnings and revenue surprises of 10.42% and 4.53%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0